Diligence memo · auto-generated · as of July 2, 2026

Silicon Therapeutics LLC

Silicon Therapeutics LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Silicon Therapeutics LLC operates in Pharma, based in Boston.

Sub-sector tags: hardware/semi, pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Silicon Therapeutics LLC has raised $6.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.2M on 2016-10-20.

Most recent recorded round closed around 2016-10-20.

Valuation (modeled)modeled

Provath models Silicon Therapeutics LLC at approximately $194M (range $7.2M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.07× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 2 months.

Last raise 9.7 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 25.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 59% of Pharma peers (310 compared).

Modeled value ranks above 76% of those peers.

Closest niche peers: Qool Therapeutics, Inc., SpringWorks Therapeutics, LLC, Caliber Therapeutics, Inc., Rodin Therapeutics, Inc., SmartPharm Therapeutics, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.